Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer - Clinical aspects and relationship with tumour response: A single-centre prospective cohort study

Annals of the Rheumatic Diseases

Volumn 77, Issue 3, 2018, Pages 393-398

  Kostine, Marie ^a   Rouxel, Leá ^a   Barnetche, Thomas ^a   Veillon, Rémi ^a   Martin, Florent ^a   Dutriaux, Caroline ^a   Dousset, Leá ^a   Pham Ledard, Anne ^a   Prey, Sorilla ^a   Beylot Barry, Marie ^a   Daste, Amaury ^a   Gross Goupil, Marine ^a   Lallier, Julie ^a   Ravaud, Alain ^a   Forcade, Edouard ^a   Bannwarth, Bernard ^a   Truchetet, Marie Elise ^a   Richez, Christophe ^a   Mehsen, Nadia ^a   Schaeverbeke, Thierry ^a  

^a BORDEAUX UNIVERSITY HOSPITAL   (France)

Author keywords

arthritis; inflammation; polymyalgia rheumatica; psoriatic arthritis; treatment

Indexed keywords

IMMUNOLOGICAL ANTINEOPLASTIC AGENT;

AGED; CELL CYCLE CHECKPOINT; CHEMICALLY INDUCED; COHORT ANALYSIS; DRUG EFFECT; FEMALE; FRANCE; HUMAN; MALE; MIDDLE AGED; NEOPLASM; PREVALENCE; PROSPECTIVE STUDY; RHEUMATIC DISEASE;

AGED; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; CELL CYCLE CHECKPOINTS; COHORT STUDIES; FEMALE; FRANCE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PREVALENCE; PROSPECTIVE STUDIES; RHEUMATIC DISEASES;

EID: 85059500850     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2017-212257     Document Type: Article

References (36)

1. The Department of Health and Human Services. FDA approves new treatment for a type of late-stage skin cancer. 2011 http://www. fda. gov/ N ewsEvents/ Newsroom/ PressAnnouncements/ ucm1193237. htm
2. Chan MM, Kefford RF, Carlino M, et al. Arthritis and tenosynovitis associated with the anti-PD1 antibody pembrolizumab in metastatic melanoma. J Immunother 2015;38:37-9.
3. Patnaik A, Kang SP, Rasco D, et al. Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors. Clin Cancer Res 2015;21:4286-93.
4. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54.
5. Westin JR, Chu F, Zhang M, et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol 2014;15:69-77.
6. Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 2015;27:450-61.
7. van der Vlist M, Kuball J, Radstake TR, et al. Immune checkpoints and rheumatic diseases: what can cancer immunotherapy teach us? Nat Rev Rheumatol 2016;12:593-604.
8. Chen DS, Irving BA, Hodi FS, et al. Molecular pathways: next-generation immunotherapy-inhibiting programmed death-ligand 1 and programmed death-1. Clin Cancer Res 2012;18:6580-7.
9. Granier C, Karaki S, Roussel H, et al. [Cancer immunotherapy: rational and recent breakthroughs]. Rev Med Interne 2016;8663:30413-1.
10. Cappelli LC, Gutierrez AK, Bingham CO, et al. Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: a systematic review of the literature. Arthritis Care Res 2017;69:1751-63.
11. Bilen MA, Subudhi SK, Gao J, et al. Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated antistriated muscle antibody. J Immunother Cancer 2016;4:36.
12. Salmon JH, Lambrecht I, Brochot P, et al. A case of arthritis under pembrolizumab. Joint Bone Spine 2017;84:243-4.
13. Kimura T, Fukushima S, Miyashita A, et al. Myasthenic crisis and polymyositis induced by one dose of nivolumab. Cancer Sci 2016;107:1055-8.
14. Cappelli LC, Gutierrez AK, Baer AN, et al. Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Ann Rheum Dis 2017;76:43-50.
15. Calabrese C, Kirchner E, Kontzias K, et al. Rheumatic immune-related adverse events of checkpoint therapy for cancer: case series of a new nosological entity. RMD Open 2017;3:e000412.
16. Belkhir R, Burel SL, Dunogeant L, et al. Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment. Ann Rheum Dis 2017;76:1747-50.
17. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.
18. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
19. Bonigen J, Raynaud-Donzel C, Hureaux J, et al. Anti-PD1-induced psoriasis: a study of 21 patients. J Eur Acad Dermatol Venereol 2017;31:e254-e257.
20. Zimmer L, Goldinger SM, Hofmann L, et al. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer 2016;60:210-25.
21. Garel B, Kramkimel N, Trouvin AP, et al. Pembrolizumab-induced polymyalgia rheumatica in two patients with metastatic melanoma. Joint Bone Spine 2017;84:233-4.
22. Le Burel S, Champiat S, Mateus C, et al. Prevalence of immune-related systemic adverse events in patients treated with anti-programmed cell death 1/antiprogrammed cell death-ligand 1 agents: a single-centre pharmacovigilance database analysis. Eur J Cancer 2017;82:34-44.
23. Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev 2016;44:51-60.
24. Boutros C, Tarhini A, Routier E, et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol 2016;13:473-86.
25. Bertrand A, Kostine M, Barnetche T, et al. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med 2015;13:211.
26. Nishimura H, Nose M, Hiai H, et al. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999;11:141-51.
27. Tivol EA, Borriello F, Schweitzer AN, et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995;3:541-7.
28. Kuehn HS, Ouyang W, Lo B, et al. Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4. Science 2014;345:1623-7.
29. Vaidya B, Pearce SH, Charlton S, et al. An association between the CTLA4 exon 1 polymorphism and early rheumatoid arthritis with autoimmune endocrinopathies. Rheumatology 2002;41:180-3.
30. Lee YH, Bae SC, Kim JH, et al. Meta-analysis of genetic polymorphisms in programmed cell death 1. Associations with rheumatoid arthritis, ankylosing spondylitis, and type 1 diabetes susceptibility. Z Rheumatol 2015;74:230-9.
31. Zhang H, Watanabe R, Berry GJ, et al. Immunoinhibitory checkpoint deficiency in medium and large vessel vasculitis. Proc Natl Acad Sci U S A 2017;114:E970-E979.
32. Calabrese L, Mariette X. The evolving role of the rheumatologist in the management of immune-related adverse events (irAEs) caused by cancer immunotherapy. Ann Rheum Dis 2017:annrheumdis-2017-212061.
33. Freeman-Keller M, Kim Y, Cronin H, et al. Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes. Clin Cancer Res 2016;22:886-94.
34. Horvat TZ, Adel NG, Dang TO , et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at memorial sloan kettering cancer center. J Clin Oncol 2015;33:3193-8.
35. Schadendorf D, Wolchok JD, Hodi FS, et al. Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: a pooled analysis of randomized phase ii and iii trials. J Clin Oncol 2017:JCO.2017.73.228.
36. Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 2014;371:2189-99.